medigraphic.com
Instituto Nacional de Salud Pública

2024, Number 3

<< Back Next >>

salud publica mex 2024; 66 (3)

Evolution of Zika prevalence in a dengue hyperendemic municipality in Southern Mexico after the outbreak of 2015 to 2017

Gaspar-Castillo C, Cortes-Escamilla A, Aparicio-Antonio R, Carnalla M, López S, Sánchez-Tacuba L, Oceguera-Cabrera A, Burrone O, González-Bonilla C, Ortiz-Navarrete V, Martínez-Barnetche J, Rodríguez MH, Alpuche-Aranda CM

Language: English
References: 34
Page: 218-225
PDF size: 299.70 Kb.


ABSTRACT

Objective. Estimate the Zika prevalence in a dengueendemic municipality in Mexico, after the outbreak of 2015 to 2017. Materials and methods. Three serosurveys were conducted in Tapachula, Chiapas, in September 2018, March 2019 and November 2019. A commercial ZIKV and DENV anti-NS1 IgG ELISA were used to estimate each prevalence, their performance and adjustment of the cut-off value were compared with an in-house DENVs and ZIKV anti-EDIII IgG ELISA and the microneutralization test. Results. The anti-NS1 ZIKV titers decreased over time, causing that Zika prevalence decreased from 78.02 to 45.22%, while anti-NS1 DENV titers increased, and the prevalence remained above 95% over a two-year period. Conclusion. Optimal Zikaprevalence estimates can be obtained in a two-years period after outbreaks in dengue-endemic areas. The extension of the Zika outbreak is significantly higher than previously reported in Tapachula, highlighting the underreport of cases based on the routine flavivirus surveillance system in Mexico.


REFERENCES

  1. Aubry M, Teissier A, Huart M, Merceron S, Vanhomwegen J, Roche C, etal. Zika Virus Seroprevalence, French Polynesia, 2014-2015. Emerg InfectDis. 2017;23(4):669-72. https://doi.org/10.3201/eid2304.161549

  2. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS,et al. Zika Virus Outbreak on Yap Island, Federated States of Micronesia.N Engl J Med. 2009;360(24):2536-43. https://doi.org/10.1056/NEJMoa0805715

  3. World Health Organization. Zika virus disease outbreak 2015-2016. Situations [Internet]. Geneva: WHO, 2016 [cited Mar 21, 2023].Available from: https://www.who.int/emergencies/situations/zika-virusoutbreak

  4. Kraemer MUG, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM,et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae.albopictus. Elife. 2015;4:e08347. https://doi.org/10.7554/eLife.08347

  5. Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, VanhomwegenJ, et al. Guillain-Barré Syndrome outbreak associated withZika virus infection in French Polynesia: a case-control study. Lancet.2016;387(10027):1531-9. https://doi.org/10.1016/S0140-6736(16)00562-6

  6. Grijalva I, Grajales-Muñiz C, González-Bonilla C, Borja-Aburto VH,Paredes-Cruz M, Guerrero-Cantera J, et al. Zika and dengue but notchikungunya are associated with Guillain-Barré syndrome in Mexico: Acase-control study. PLoS Negl Trop Dis. 2020;14(12):e0008032. https://doi.org/10.1371/JOURNAL.PNTD.0008032

  7. Brasil P, Pereira JP, Moreira ME, Ribeiro-Nogueira RM, DamascenoL, Wakimoto M, et al. Zika Virus infection in pregnant women in Riode Janeiro. N Engl J Med [Internet]. 2016;375(24):2321-34. http://doi.org/10.1056/NEJMoa1602412

  8. Secretaría de Salud, Dirección General de Epidemiología. Boletín Epidemiológico.Sistema Nacional de Vigilancia Epidemiológica Sistema Único deInformación 2023 [Internet]. Mexico: Secretaría de Salud, 2017:45 [citedApr 26, 2023]. Available from: https://www.gob.mx/salud/documentos/boletinepidemiologico-sistema-nacional-de-vigilancia-epidemiologicasistema-unico-de-informacion-261547

  9. Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengueinfection. Nat Rev Dis Prim. 2016;2:16055. https://doi.org/10.1038/nrdp.2016.55

  10. Paixão ES, Barreto F, da Glória Teixeira M, da Conceição Costa M,Rodrigues LC. History, Epidemiology, and Clinical Manifestations of Zika:A Systematic Review. Am J Public Health. 2016;106(4):606-12. https://doi.org/10.2105/AJPH.2016.303112

  11. Ioos S, Mallet HP, Leparc-Goffart I, Gauthier V, Cardoso T, Herida M.Current Zika virus epidemiology and recent epidemics. Med Mal Infect.2014;44(7):302-7. https://doi.org/10.1016/j.medmal.2014.04.008

  12. Judice CC, Tan JJL, Parise PL, Kam YW, Milanez GP, Leite JA, et al. Efficientdetection of Zika virus RNA in patients’ blood from the 2016 outbreakin Campinas, Brazil. Sci Rep. 2018;8(1):1-7. https://doi.org/10.1038/s41598-018-22159-2

  13. Murhekar MV, Clapham H. COVID-19 serosurveys for public healthdecision making. Lancet Glob Heal. 2021;9(5):e559-60. https://doi.org/10.1016/S2214-109X(21)00057-7

  14. L’Huillier AG, Hamid-Allie A, Kristjanson E, Papageorgiou L, Hung S,Wong CF, et al. Evaluation of euroimmun anti-zika virus IgM and IgGenzyme-linked immunosorbent assays for zika virus serologic testing. JClin Microbiol. 2017;55(8):2462-71. https://doi.org/10.1128/JCM.00442-17

  15. Andrade P, Gimblet-Ochieng C, Modirian F, Collins M, CárdenasM, Katzelnick LC, et al. Impact of pre-existing dengue immunity onhuman antibody and memory B cell responses to Zika. Nat Commun.2019;10(1):938. https://doi.org/10.1038/S41467-019-08845-3

  16. Safronetz D, Sloan A, Stein DR, Mendoza E, Barairo N, Ranadheera C,et al. Evaluation of 5 Commercially Available Zika Virus Immunoassays.2017;23(9):1577-80. https://doi.org/10.3201/eid2309.162043

  17. van Meer MPA, Mögling R, Klaasse J, Chandler FD, Pas SD, van der EijkAA, et al. Re-evaluation of routine dengue virus serology in travelers inthe era of Zika virus emergence. J Clin Virol. 2017;92:25-31. https://doi.org/10.1016/j.jcv.2017.05.001

  18. Zaidi MB, Cedillo-Barron L, González y Almeida ME, Garcia-CorderoJ, Campos FD, Namorado-Tonix K, et al. Serological tests reveal significantcross-reactive human antibody responses to Zika and Dengue virusesin the Mexican population. Acta Trop. 2019;201:105201. https://doi.org/10.1016/j.actatropica.2019.105201

  19. Roehrig JT, Hombach J, Barrett ADT. Guidelines for plaque-reductionneutralization testing of human antibodies to dengue viruses. Viral Immunol.

  20. 2008;21(2):123-32. https://doi.org/10.1089/vim.2008.000720. Denis J, Attoumani S, Gravier P, Tenebray B, Garnier A, Briolant S,et al. High specificity and sensitivity of Zika EDIII-based ELISA diagnosishighlighted by a large human reference panel. PLoS Negl Trop Dis.2019;13(9):e0007747. https://doi.org/10.1371/journal.pntd.0007747

  21. Cortes-Escamilla A, Roche B, Rodríguez-López MH, López Gatell-Ramírez H, Alpuche-Aranda CM. Spatiotemporal patterns of dengue andZika incidence during the 2015-2018 outbreak of Zika in Mexico. SaludPublica Mex. 2022;64(5):478-87. https://doi.org/10.21149/13584

  22. Fernández-Salas I, Díaz-González EE, López-Gatell H, Alpuche-ArandaC. Chikugunya and zika virus dissemination in the Americas: differentarboviruses reflecting the same spreading routes and poor vector-controlpolicies. Curr Opin Infect Dis. 2016;29(5):467-75. https://doi.org/10.1097/QCO.0000000000000304

  23. Gaspar-Castillo C, Cortes-Escamilla A, Aparicio-Antonio R, Carnalla M,Lopez S, Sánchez-Tacuba L, et al. Appendix S1. Evolution of Zika prevalencein a dengue hyper-endemic municipality in Southern Mexico after theoutbreak of 2015 to 2017 [Internet]. Figshare. 2024 [cited Jan 25, 2024].Available from: https://doi.org/10.6084/M9.FIGSHARE.25044098.V2

  24. EUROIMMUN. Antibodies against emerging viruses and otherpathogens [Internet]. Lübeck, Germany: EUROIMMUN [cited Jul 26,2019]. Available from: https://www.euroimmun.com/products/indications/infektions-serologie/tropenkrankheiten.html

  25. Poggianella M, Campos JLS, Chan KR, Tan HC, Bestagno M, Ooi EE,et al. Dengue E Protein domain III-Based DNA immunisation inducesstrong antibody responses to all four viral serotypes. PLoS NeglTrop Dis. 2015;9(7):e0003947. https://doi.org/10.1371/JOURNAL.PNTD.0003947

  26. Vorndam V, Beltran M. Enzyme-linked immunosorbent assay-formatmicroneutralization test for dengue viruses. Am J Trop Med Hyg.2002;66(2):208-12. https://doi.org/10.4269/ajtmh.2002.66.208

  27. Rogan WJ, Gladen B. Estimating prevalence from the results of ascreening test. Am J Epidemiol [Internet]. 1978;107(1):71-6. https://doi.org/10.1093/OXFORDJOURNALS.AJE.A112510

  28. Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A,Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in thegeneral population and high-risk occupational groups across 18 citiesin Iran: a population-based cross-sectional study. Lancet Infect Dis.2021;21(4):473-81. https://doi.org/10.1016/S1473-3099(20)30858-6

  29. Huzly D, Hanselmann I, Schmidt-Chanasit J, Panning M. High specificityof a novel Zika virus ELISA in European patients after exposureto different flaviviruses. Euro Surveill. 2016;21(16):30203. https://doi.org/10.2807/1560-7917.ES.2016.21.16.30203

  30. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ,et al. Genetic and serologic properties of Zika virus associated with anepidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14(8):1232-9.https://doi.org/10.3201/eid1408.080287

  31. Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J,Edupuganti S, et al. Human antibody responses after dengue virus infectionare highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A.2016;113(28):7852-7. https://doi.org/10.1073/PNAS.1607931113

  32. Secretaría de Salud, Dirección General de Epidemiología. PanoramaEpidemiológico de Dengue 2021 [Internet]. Mexico: Secretaría de Salud,2022 [cited Apr 13, 2022]. Available from: https://www.gob.mx/salud/documentos/panorama-epidemiologico-de-dengue-2022

  33. Katzelnick LC, Bos S, Harris E. Protective and enhancing interactionsamong dengue viruses 1-4 and Zika virus. Curr Op Virol. 2020;43:59-70.https://doi.org/10.1016/j.coviro.2020.08.006

  34. Rodríguez-Barraquer I, Solomon SS, Kuganantham P, Srikrishnan AK,Vasudevan CK, Iqbal SH, et al. The hidden burden of dengue and chikungunyain Chennai, India. PLoS Negl Trop Dis. 2015;9(7):e0003906. https://doi.org/10.1371/journal.pntd.0003906




2020     |     www.medigraphic.com